John Paul Leach
Overview
Explore the profile of John Paul Leach including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
36
Citations
656
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Benoist C, Boccaletti S, Leach J, Cattaneo A, Chaplin A, Antunes L, et al.
Epilepsy Behav
. 2023 Nov;
149:109540.
PMID: 38006844
Objectives: To describe the demographics, clinical characteristics, drug treatment outcomes, healthcare resource utilization, and injuries among people with focal drug-resistant epilepsy (F-DRE) analysed separately for six European countries. Methods: We...
2.
Mitchell J, Noble A, Baker G, Batchelor R, Brigo F, Christensen J, et al.
Trials
. 2022 Nov;
23(1):943.
PMID: 36397081
Background: A Core Outcome Set (COS) is a standardised list of outcomes that should be reported as a minimum in all clinical trials. In epilepsy, the choice of outcomes varies...
3.
Askarieh A, MacBride-Stewart S, Kirby J, Fyfe D, Hassett R, Todd J, et al.
Seizure
. 2022 Jun;
100:24-29.
PMID: 35728343
Purpose: To evaluate service access for women with epilepsy (WWE) during pregnancy; to determine seizure frequency and rates of adherence to anti-seizure medication (ASM). Methods: Between June 2019-June 2020, pregnant...
4.
McTaggart S, MacColl G, Gronkowski K, Wood R, Leach J, Bennie M
BMJ Open
. 2022 Apr;
12(4):e058312.
PMID: 35418434
Objective: To examine the impact of Medicines and Healthcare products Regulatory Agency (MHRA) safety alerts on valproate prescribing among women aged 14-45 years in Scotland and examine trends in pregnancies...
5.
Marson A, Burnside G, Appleton R, Smith D, Leach J, Sills G, et al.
Health Technol Assess
. 2021 Dec;
25(75):1-134.
PMID: 34931602
Background: Levetiracetam (Keppra, UCB Pharma Ltd, Slough, UK) and zonisamide (Zonegran, Eisai Co. Ltd, Tokyo, Japan) are licensed as monotherapy for focal epilepsy, and levetiracetam is increasingly used as a...
6.
Craig J, Scott S, Leach J
Pract Neurol
. 2021 Dec;
22(2):98-106.
PMID: 34887343
Pregnancy is a time of physical, physiological and psychological challenge. For women with epilepsy, as well as its potential for joy and fulfilment, pregnancy may bring additional risks and difficulties....
7.
Hope D, Dewar A, Hothersall E, Leach J, Cameron I, Jaap A
BMJ Open
. 2021 Sep;
11(9):e046056.
PMID: 34479932
Objective: To measure Differential Attainment (DA) among Scottish medical students and to explore whether attainment gaps increase or decrease during medical school. Design: A retrospective analysis of undergraduate medical student...
8.
Marson A, Burnside G, Appleton R, Smith D, Leach J, Sills G, et al.
Lancet
. 2021 Apr;
397(10282):1375-1386.
PMID: 33838758
Background: Valproate is a first-line treatment for patients with newly diagnosed idiopathic generalised or difficult to classify epilepsy, but not for women of child-bearing potential because of teratogenicity. Levetiracetam is...
9.
Marson A, Burnside G, Appleton R, Smith D, Leach J, Sills G, et al.
Lancet
. 2021 Apr;
397(10282):1363-1374.
PMID: 33838757
Background: Levetiracetam and zonisamide are licensed as monotherapy for patients with focal epilepsy, but there is uncertainty as to whether they should be recommended as first-line treatments because of insufficient...
10.
Balabanova S, Taylor C, Sills G, Burnside G, Plumpton C, Smith P, et al.
BMJ Open
. 2020 Aug;
10(8):e040635.
PMID: 32847927
Introduction: Antiepileptic drugs (AEDs) are the mainstay of epilepsy treatment. Over the past 20 years, a number of new drugs have been approved for National Health Service (NHS) use on...